Table 2.
Cetuximab biosimilars.
| Product name | Development stage | Involved company | |
|---|---|---|---|
| 1 | Cetuximab biosimilar ONS1055 | Preclinical | Oncobiologics and Outlook Therapeutics |
| 2 | Cetuximab biosimilar RPH002 | Phase III | R-Pharm |
| 3 | Cetuximab biosimilar ONS1055 | Preclinical | Viropro, Oncobiologics, and Outlook Therapeutics |
| 4 | Cetuximab biosimilar ABP494 | Preclinical | Actavis, Allergan, and Amgen |
| 5 | Cetuximab biosimilar HLX05 | Preclinical | Shanghai Henlius Biotech Inc |
| 6 | Cetuximab biosimilar ABP494 | Preclinical | Actavis, Allergan, and Amgen |
| 7 | Cetuximab platform | Research | PlantForm Corporation |
| 8 | Cetuximab biosimilar CT-P15 | Research | Celltrion |
| 9 | Cetuximab biosimilar BNV003 | Research | Bionovis SA |
| 10 | Cetuximab platform | Research | PharmaPraxis |
| 11 | Cetuximab biosimilar CMAB009 | Phase I/II/III | Mabtech, Shanghai Zhangjiang Biotechnology, and Sinomab |
| 12 | Cetuximab biosimilar KL 140 | Phase I/II/III | Sichuan Kelun Pharmaceutical Research Institute |
| 13 | Cetuximab biosimilar CDP-1 | Phase I/II/III | Dragonboat Biopharmaceutical |
| 14 | Cetuximab biosimilar (STI-001) | Phase III | Mabtech |
| 15 | Cetuximab biosimilar | Research | BioXpress Therapeutics |